] i ) is key to contractility of airway smooth muscle (ASM). Studies from our own laboratory and by others showed that proinflammatory cytokines such as TNF␣ and IL-13 increase agonist-induced [Ca 2ϩ ] i response in ASM (8, 31, 35, 38) . The sarcoplasmic reticulum (SR) is a specialized intracellular membrane system in smooth and striated muscle that is involved in the uptake, storage, and release of Ca . In smooth muscle (as in other muscles), the SR Ca 2ϩ ATPase (SERCA) is the sole mechanism for replenishing SR Ca 2ϩ stores, with two Ca 2ϩ ions pumped into the SR for every ATP consumed against a Ca 2ϩ gradient of ϳ1 M in the cytosol vs. 1 mM in the SR lumen (16, 22) . Thus, inflammation-induced increase in [Ca 2ϩ ] i may be mediated by interference with SERCA expression and function such that SR Ca 2ϩ reuptake is impaired. There is currently very limited data on the regulation of SERCA in ASM (7, 17, 30) . In cardiac muscle, SERCA is normally modulated in an inhibitory fashion by the protein phospholamban (PLB) (33). Previous studies in bovine pulmonary artery (26) and murine gastrointestinal smooth muscle (14) have shown that, as in cardiac muscle, cyclic nucleotides, Ca 2ϩ /CaM-dependent protein kinase (CaMKII), and/or protein kinase C phosphorylate PLB, resulted in disinhibition of SERCA and accelerated SR Ca 2ϩ reuptake. However, in porcine coronary artery smooth muscle, while there is evidence of CaMKII phosphorylation of SERCA with accompanying increase in SERCA activity, PLB has not been detected in that tissue (12). In this regard, whether PLB itself regulates SERCA in ASM (as in cardiac or other smooth muscles) is not at all clear. We recently reported that porcine ASM does express PLB, that PLB regulation by CaMKII occurs, and decreased PLB expression (using small interference RNA; siRNA) increases SR Ca 2ϩ refilling following agonist exposure (30). However, in that study, we found that even with PLB suppression by siRNA, additional modulation of Ca 2ϩ reuptake can occur via CaMKII. Accordingly, the expression and contribution of PLB to SR Ca 2ϩ refilling may be tissue-and speciesspecific. In this regard, there is currently no information on SERCA regulation by PLB in human ASM. Furthermore, there is no information on alterations in SERCA with airway inflammation that could contribute to increased [Ca 2ϩ ] i and thus increased bronchoconstriction.
release and reuptake are key components of ASM [Ca 2ϩ ]i regulation. Ca 2ϩ reuptake occurs via sarcoendoplasmic reticulum Ca 2ϩ ATPase (SERCA) and is regulated by the inhibitory protein phospholamban (PLB) in many cell types. In human ASM, we tested the hypothesis that inflammation increases PLB, thus inhibiting SERCA function, and leading to maintained [Ca 2ϩ ]i levels. Surprisingly, we found that human ASM does not express PLB protein (although mRNA is detectable). Overnight exposure to the proinflammatory cytokines TNF␣ and IL-13 did not induce PLB expression, raising the issue of how SERCA is regulated. We then found that direct SERCA phosphorylation (via CaMKII) occurs in human ASM. In fura-2-loaded human ASM cells, we found that the CaMKII antagonist KN-93 significantly slowed the rate of fall of [Ca 2ϩ ]i transients induced by ACh or bradykinin (in zero extracellular Ca 2ϩ ), suggesting a role for CaMKII-mediated SERCA regulation. SERCA expression was decreased by cytokine exposure, and the rate of fall of [Ca 2ϩ ]i transients was slowed in cells exposed to TNF␣ and IL-13. Cytokine effects on Ca 2ϩ reuptake were unaffected by additional exposure to KN-93. These data indicate that in human ASM, SERCA is regulated by mechanisms such as CaMKII and that airway inflammation maintains [Ca 2ϩ ]i levels by decreasing SERCA expression and slowing Ca 2ϩ reuptake.
sarcoendoplasmic reticulum Ca 2ϩ ATPase; calmodulin; calmodulin kinase; tumor necrosis factor-␣; interleukin-13 REGULATION OF INTRACELLULAR CA 2ϩ ([Ca 2ϩ ] i ) is key to contractility of airway smooth muscle (ASM). Studies from our own laboratory and by others showed that proinflammatory cytokines such as TNF␣ and IL-13 increase agonist-induced [Ca 2ϩ ] i response in ASM (8, 31, 35, 38) . The sarcoplasmic reticulum (SR) is a specialized intracellular membrane system in smooth and striated muscle that is involved in the uptake, storage, and release of Ca . In smooth muscle (as in other muscles), the SR Ca 2ϩ ATPase (SERCA) is the sole mechanism for replenishing SR Ca 2ϩ stores, with two Ca 2ϩ ions pumped into the SR for every ATP consumed against a Ca 2ϩ gradient of ϳ1 M in the cytosol vs. 1 mM in the SR lumen (16, 22) . Thus, inflammation-induced increase in [Ca 2ϩ ] i may be mediated by interference with SERCA expression and function such that SR Ca 2ϩ reuptake is impaired. There is currently very limited data on the regulation of SERCA in ASM (7, 17, 30) . In cardiac muscle, SERCA is normally modulated in an inhibitory fashion by the protein phospholamban (PLB) (33) . Previous studies in bovine pulmonary artery (26) and murine gastrointestinal smooth muscle (14) have shown that, as in cardiac muscle, cyclic nucleotides, Ca 2ϩ /CaM-dependent protein kinase (CaMKII), and/or protein kinase C phosphorylate PLB, resulted in disinhibition of SERCA and accelerated SR Ca 2ϩ reuptake. However, in porcine coronary artery smooth muscle, while there is evidence of CaMKII phosphorylation of SERCA with accompanying increase in SERCA activity, PLB has not been detected in that tissue (12) . In this regard, whether PLB itself regulates SERCA in ASM (as in cardiac or other smooth muscles) is not at all clear. We recently reported that porcine ASM does express PLB, that PLB regulation by CaMKII occurs, and decreased PLB expression (using small interference RNA; siRNA) increases SR Ca 2ϩ refilling following agonist exposure (30) . However, in that study, we found that even with PLB suppression by siRNA, additional modulation of Ca 2ϩ reuptake can occur via CaMKII. Accordingly, the expression and contribution of PLB to SR Ca 2ϩ refilling may be tissue-and speciesspecific. In this regard, there is currently no information on SERCA regulation by PLB in human ASM. Furthermore, there is no information on alterations in SERCA with airway inflammation that could contribute to increased [Ca 2ϩ ] i and thus increased bronchoconstriction.
In the present study, we hypothesized that inflammation leads to increased PLB expression and inhibition of SERCA in human ASM, thus decreasing SR Ca 2ϩ reuptake and contributing to inflammation-induced increase in [Ca 2ϩ ] i . We used freshly isolated ASM tissue and fura-2-loaded ASM cells to test this hypothesis.
MATERIALS AND METHODS
Chemicals. Reagents for electrophoresis were obtained from BioRad Laboratories (Hercules, CA); anti-PLB monoclonal antibody and anti-SERCA2 ATPase polyclonal antibody were from Abcam (Cambridge, MA); anti-GAPDH polyclonal antibody was from cell signaling; PLB siRNA was from Santa Cruz Biotechnology (Santa Cruz, CA); DMEM-Ham's F-12 medium, penicillin/streptomycin, Lipofectamine 2000, and fura-2-AM were from Invitrogen (Carlsbad, CA); and TNF␣, IL-13, and KN-93 were from Calbiochem (San Diego, CA). All other chemicals were obtained from Sigma-Aldrich (St. Louis, MO) unless otherwise noted.
Human ASM. ASM was obtained from surgical waste lung tissue from patients undergoing thoracic surgery at Mayo Clinic Rochester with approval of the Mayo Clinic Institutional Review Board (con-sidered exempt from IRB review since no patient information was accessible to the investigators). Tissues were initially placed in Hanks' balanced salt solution (HBSS; Invitrogen) with 2.5 mM extracellular Ca 2ϩ . Normal areas of the lung sample and the bronchioles were identified by the pathologists. The bronchioles were freed of cartilage, epithelium, and surrounding tissues. Samples were finely minced in ice-cold Ca 2ϩ -free HBSS (0 Ca 2ϩ HBSS). For some biochemical work, these tissue fragments were homogenized using cell lysis buffer. For single cell work, ASM cells were isolated as previously described (25) . Briefly, following collagenase dissociation and ovomucoid/albumin separation, cell pellets were resuspended in DMEM/F-12 medium with 10% FBS, centrifuged, and resuspended. Cells were plated in sterile culture flasks and grown in a humidified incubator at 95% air-5% CO2 in DMEM-Ham's F-12 medium supplemented with 10% FBS. All experiments were performed in cells before the second passage. In subsets of samples, ASM phenotype was identified by immunostaining for smooth muscle actin and myosin and by expression of receptors for agonists commonly used for the airway.
PLB mRNA expression. Total RNA was extracted from cells using the RNeasy Mini kit (Qiagen) following the manufacturer's protocol. Before real-time RT-PCR, microfluidic technology using the BioAnalyzer 2100 (Agilent Technologies) was used to assess RNA quantity and integrity in accordance with the manufacturer's protocol.
Reverse transcription. Total RNA (100 ng) was reverse transcribed using the AffinityScript QPCR cDNA Synthesis kit (Stratagene) following the kit protocol. Briefly, sample RNA, oligo(dT), random hexamers, 2ϫ First Strand mix, AffinityScript RT/RNase Block enzyme mix, and RNase free sterile water to 20 l were incubated at 25°C for 5 min, 42°C for 15 min, and 95°C for 5 min and chilled on ice. Reverse transcription reactions were done in duplicate.
Real-time PCR. PCR primers were designed for real-time RT-PCR using LightCycler Probe Design software (version 1.0; Roche Molecular) and are as follows: 5Ј-ATCTTTCTCTCGACCACT-3Ј and 5Ј-AGCATCACGATGATACAG-3Ј for PLB, and 5Ј-ATCCGCAAA-GACCTGT-3Ј and 5Ј-GTCCGCCTAGAAGCAT-3Ј for actin. For gene expression analysis, 2 l of the reverse transcription reaction was added to a reaction mix containing 1ϫ SYBR Green I Master (Roche Molecular), either 2.5 mM MgCl2 for PLB or 2.0 mM for actin MgCl 2, and 0.5 M of the respective primer pair. Amplification and quantitation of mRNA was performed on a LightCycler (Roche Molecular) using the following parameters: for PLB, 10 min at 95°C followed by 35 cycles of 15 s at 95°C, 10 s at 59°C, and 8 s at 72°C, and for actin, 10 min at 95°C followed by 35 cycles of 15 s at 95°C, 10 s at 59°C, and 11 s at 72°C. Fluorescence measurements were taken at the end of each cycle (product extension period). Following amplification, a melting curve analysis was performed to verify amplification product specificity. Briefly, amplification products were denatured at 95°C and then quickly cooled to 65°C for 15 s. Products were then heated at a rate of 0.1°C/s to a final temperature of 95°C while continuously measuring fluorescence. The derivative of the melting curve fluorescence (ϪdF/dT) was plotted vs. temperature thus yielding melting peaks indicative of products generated during amplification. The lack of primer-dimer complexes and the presence of an appropriate single peak in the resultant melting curve were indicators of correct amplification products. In addition, PLB amplification products were electrophoresed on 1.0% agarose and sequenced to verify the nature of the amplified product. All PCR reactions were performed in duplicate for each reverse transcription product.
Quantitative analyses. An amplification fluorescence plot was generated for each sample with LightCycler software (version 4.0, Roche Molecular) using the second derivative method. From this plot a threshold cycle value was calculated that corresponds to the cycle number at which fluorescence was detected above threshold. This threshold cycle value was used to calculate the amount of PLB cDNA relative to ␤-actin cDNA.
Immunoblotting of PLB and SERCA2. In addition to human ASM tissue and ASM cells, tissue samples from other organs/species were also probed for PLB to rule out potential problems of antibody specificity or lack of epitope recognition. Human pulmonary artery was obtained from the above lung samples and denuded of endothelium and adventitia. Porcine ASM (previously shown to express PLB) (30) was excised from trachea obtained from the local abattoir.
Previous studies have demonstrated that the SERCA2 isoform is commonly expressed in smooth muscles (11, 32) . Furthermore, SERCA2 is known to be associated with PLB (11, 32) . Accordingly, we selected this isoform for study.
Western immunoblotting techniques were used for detection and estimation of the relative amounts of PLB and SERCA2. Tissue homogenates (25 g of protein) were first subjected to SDS-PAGE in 4 -15% gels, and the fractionated proteins were transblotted to polyvinylidene difluoride membranes (Bio-Rad Laboratories). Membranes were blocked for 1 h with 5% milk in Tris-buffered saline containing 0.1% Tween, incubated with appropriate primary antibody overnight at 4°C, washed with Tris-buffered saline containing 0.1% Tween, detected with horseradish peroxidase-conjugated secondary antibodies, and developed with Supersignal West Pico Chemiluminescent Substrate (Pierce Chemical, Rockford, IL).
Determination of Ca 2ϩ uptake. ATP-dependent, oxalate-facilitated Ca 2 uptake by human ASM homogenates was determined using the Millipore filtration technique. After determination of the specific activity of the 45 Ca 2ϩ isotope (Perkin Elmer), the loading medium (LM; total volume 1 ml), consisting of 50 mM Tris-maleate (pH 6.8), 5 mM MgCl2, 5 mM NaN3, 120 mM KCl, 0.1 mM EGTA, 5 mM potassium oxalate, 5 mM ATP, 0.025 mM ruthenium red, 0.1 mM 45 Ca 2ϩ (ϳ8 ϫ 10 3 cpm/nmol), and homogenate (40 g), was prepared. The final concentration of treatment groups KN-93 (10 M), exogenous CaM (3 M), and thapsigargin (1 M), with controls containing vehicle alone and the LM (with or without KN-93, CaM, or thapsigargin) was then incubated for 3 min at 37°C. Before the addition of human ASM homogenate, duplicate aliquots were drawn from treatment and control tubes for assessment of blank counts per minute at time 0. Immediately after the addition of homogenate, 45 Ca 2ϩ uptake was monitored over a 45-min period by transfer of the aliquots at 5, 15, 30, and 45 min onto GF/B 24-mm Whatmann filters. The filters were vacuum-dried, and reactions were stopped by the addition of ice-cold 10 mM Tris-maleate (pH 6.8) wash buffer. Filters were then rinsed five times with 5 ml of the wash buffer, air-dried, and immersed in 10 ml of Ultima-Gold scintillation liquid (Perkin Elmer) for measurement of counts per minute using a Beckman scintillation counter. Background correction was made by subtraction of values obtained after incubation of homogenate in the absence of ATP in the loading medium. (12, 30) .
PLB knockdown by siRNA. A 20-to 25-nucleotide target-specific siRNA corresponding to human PLB mRNA was selected for PLB knockdown. Human ASM were isolated as described above and grown in growth medium consisting of DMEM/Ham's F-12 medium containing 10% FBS and 1% Pen-Strep until they reached ϳ70% confluence. Cells were then rinsed in serum-and antibiotic-free DMEM/Ham's F-12 medium and transfected using 50 nM siRNA and Lipofectamine 2000. Fresh growth medium was added 6 h after addition of siRNA, and the cells were analyzed 48 h after transfection (30) .
[ ]i measurements in ASM have been previously described (31, 38) . Briefly, ASM cells plated in eight-well borosilicate coverglass chambers were incubated for 45 min in 5 M fura-2-AM, washed, and perfused with HBSS. Cells were visualized with a real-time fluorescence imaging system (MetaFluor; Universal Imaging, Downingtown, PA) on a Nikon 300 inverted microscope (Fryer Instruments, Edina, MN). The dye was alternately excited at 340 and 380 nm (Lambda 10 -2 filter changer; Sutter Instrument, Novato, CA), and emissions were collected with a 510-nm barrier filter. Images were acquired at 1.33 Hz with a Photometric Cascade digital camera system (Roper Scientific, Tucson, AZ), and results were expressed as the ratio of emissions at 340 nm to emissions at 380 nm. Cells were initially perfused with HBSS, and baseline fluorescence was established. [Ca 2ϩ ]i responses of 10 -15 cells/chamber were obtained using individual, software-defined regions of interest. The rate of fall of the [Ca 2ϩ ]i response (see RESULTS for individual protocols) starting from the peak value was estimated using a single-exponential fitting curve (Origin statistical software).
Statistical analysis. Experiments were performed using tissues obtained from six different patients. SERCA protein expression (measured by densitometry) was compared between groups using unpaired t-test. A value of P Ͻ 0.05 was accepted as significant. All results are expressed as means Ϯ SE.
RESULTS

PLB protein is not detectable in human ASM.
Quantitative RT-PCR revealed that PLB mRNA is present in human ASM (Fig. 1) . Sequencing of amplification products following electrophoresis on 1.0% agarose verified their identity as PLB mRNA (Fig. 1) . Western analysis showed that both human pulmonary artery smooth muscle and porcine ASM displayed significant PLB protein, confirming the ability of the antibody to detect PLB from different species and tissues. Surprisingly, no PLB expression was detected in either lysates of enzymatically dissociated human ASM cells or in tissue homogenates of human bronchi (Fig. 2) , in spite of the mRNA present. There was abundant expression of SERCA2 in porcine ASM (isolated as described previously) (30), human ASM, as well as pulmonary artery. To verify that the protein content in the gel electrophoresis was not a limiting factor, in some experiments, 100 g of human bronchial homogenate was loaded, with no PLB detectable even under these conditions (data not shown). The relative PLB-to-SERCA2 ratio, commonly used as a regulatory index of Ca 2ϩ uptake (18) , was obviously zero, compared with human pulmonary artery.
PLB siRNA has no effect on SR Ca 2ϩ reuptake. In both control (nontransfected) and PLB siRNA-transfected, fura-2-loaded human ASM cells, baseline [ influx/efflux had no further effect. Under these conditions of functionally isolated SR, stimulation with 1 M ACh or 10 nM bradykinin produced characteristic biphasic [Ca 2ϩ ] i responses involving a rapid, initial peak response, followed by a decay to plateau levels above baseline. The rate of fall of the initial response was measured as an index of SR Ca 2ϩ reuptake and was found to be comparable between control and siRNAtransfected ASM cells for both ACh and bradykinin (Fig. 3) .
Effect of CaMKII inhibition on SR Ca 2ϩ reuptake. In fura-2-loaded human ASM cells, [Ca 2ϩ ] i responses to 1 M ACh or to 10 nM bradykinin were first evaluated. Cells were then thoroughly washed in HBSS (15-20 min), and [Ca 2ϩ ] i responses to the same agonist were reevaluated in the additional presence of the CaMKII inhibitor KN-93 (1 M; 15-min preexposure before agonist stimulation). KN-93 significantly slowed the rate of fall of [Ca 2ϩ ] i responses to ACh as well as bradykinin (P Ͻ 0.05 for KN-93 effect with each agonist; Fig. 4 ] i responses to either agonist (P Ͻ 0.05; Fig. 4 ). In separate experiments using human ASM homogenates, we evaluated the rate of 45 Ca uptake as an index of SR Ca 2ϩ reuptake under specific conditions. Under control conditions when ATP and oxalate were present, steady SERCA activity was detected, resulting in increasing nanomoles of 45 Ca uptake over a 45-min period (Fig. 5) . Addition of exogenous CaM slightly increased the rate of 45 Ca uptake, indicating sufficient endogenous CaMKII was already present. Addition of KN-93 substantially slowed 45 Ca uptake ( Fig. 5 ; P Ͻ 0.05), whereas 1 M thapsigargin [SERCA inhibitor (15) ] decreased uptake even further (P Ͻ 0.05).
Effect of cytokines on PLB and SERCA2 in human ASM. Overnight exposure of human ASM cells or tissues to 20 ng/ml TNF␣ or IL-13 did not induce PLB protein expression, although human pulmonary artery (not exposed to cytokines) showed PLB expression within the same immunoblot (Fig. 6) . In contrast to lack of PLB expression, SERCA2 expression was significantly decreased by exposure to both TNF␣ and IL-13 ( Fig. 6 ; P Ͻ 0.05).
Effect of cytokines on SR Ca 2ϩ reuptake. Human ASM cells exposed overnight to medium only (control) vs. 20 ng/ml TNF␣ or IL-13 were loaded with fura-2, and [Ca 2ϩ ] i responses to 1 M ACh or to 10 nM bradykinin were evaluated in the absence of extracellular Ca 2ϩ and blocked plasma membrane Ca 2ϩ fluxes (see above). The rates of fall of [Ca 2ϩ ] i responses were used as indices of SR Ca 2ϩ reuptake. Compared with controls, in cells exposed to TNF␣ as well as IL-13, SR Ca 2ϩ reuptake was substantially slowed ( Fig. 7 ; P Ͻ 0.05 for either cytokine and either agonist). In TNF␣-as well as IL-13-exposed ASM cells, the rate of fall of [Ca 2ϩ ] i responses to ACh or bradykinin (in zero extracellular Ca 2ϩ and 1 mM La 3ϩ ) was largely unaffected by preexposure to KN-93 compared with controls (not exposed to cytokines) where KN-93 substantially slowed reuptake (Fig. 8) . 
DISCUSSION
The novel results of the present study indicate that unlike skeletal and cardiac muscles and even porcine ASM, human ASM does not express the inhibitory protein PLB. Instead, CaMKII may play a role in regulation of SERCA in human ASM, evidenced by the slowing of SR Ca 2ϩ reuptake in the presence of the CaMKII inhibitor KN-93. Proinflammatory cytokines such as TNF␣ and IL-13 do not induce PLB expression (as they do other [Ca 2ϩ ] i regulatory proteins), although PLB mRNA is clearly present. Instead, SERCA2 expression appears to be decreased, potentially contributing to the slowing of SR Ca 2ϩ reuptake in human ASM cells exposed to cytokines. These effects of proinflammatory cytokines may contribute, at least in part, to previously observed increases in [ Regulation of SERCA. The inhibitory role of PLB in SERCA regulation is well established in cardiac muscle (33) . In vascular smooth muscle, PLB phosphorylation/dephosphorylation by signaling mechanisms such as cyclic nucleotides, Ca 2ϩ / CaM kinase, and/or PKC disinhibits SERCA and accelerates SR Ca 2ϩ reuptake (26 -28) . More recently, siRNA suppression of PLB expression has also been shown to improve Ca 2ϩ uptake affinity and activity (37) . Whether PLB is involved in regulating SERCA activity in ASM is not as well studied (17, 30) . In cultured ASM cells from transgenic mice overexpressing ␣ 2 -adrenoceptors, decreased PLB expression has been reported (17) In a recent study, we reported that PLB is expressed in porcine ASM cells and that PLB siRNA transfection results in significantly faster decline in [Ca 2ϩ ] i responses to bronchoconstrictor agonist (under conditions of functionally isolated SR as in the present study), indicating increased activity of SERCA and confirming a regulatory role of PLB on Ca 2ϩ uptake in that particular tissue. Given the limited but positive data on PLB in ASM, we expected human ASM to also express PLB. However, repeated studies in human ASM cells, as well as bronchi, using multiple, complementary techniques showed no PLB expression. Immunoprecipitation revealed a miniscule amount of PLB protein, whereas immunostaining showed Ͻ1% of cells with positive staining for PLB (data not shown). However, within the same Western blots or immunoprecipitates, other tissues (e.g., human pulmonary artery and porcine ASM) displayed significant PLB levels. Specificity of the PLB antibody for human PLB has been previously demonstrated by other groups (21, 24) and also confirmed by using positive controls from both human and other species in the present study. Accordingly, it is likely that although PLB mRNA is present in human ASM, the mRNA is not being translated, or if it is, the extent of translation or the level of stable protein is minimal (as suggested by the miniscule amount noted with immunoprecipitation of large amounts of ASM protein). To verify the miniscule amount of PLB that may be present (but not detected by Western blot), we further used PLB siRNA to knockdown the encoding mRNA and determine whether SR Ca 2ϩ reuptake is affected. Unlike our results in porcine ASM (30) , PLB siRNA transfection did not significantly alter the rate of fall of [Ca 2ϩ ] i responses (an index of SR Ca 2ϩ reuptake under conditions of functionally isolated SR). These data indicate that any small amount of PLB protein, if present, is physiologically inconsequential. Even if there is minimal expression of PLB that was not detected (or altered) by our techniques, the fact that the PLB/SERCA ratio (typically ϳ0.5) would be miniscule suggests that PLB does not play a significant functional role in human ASM SERCA regulation.
The lack of PLB may not be unique to human ASM. Damiani et al. (6) suggested lack of PLB expression in rat slow-twitch skeletal muscle. Grover et al. (12) reported no PLB in coronary artery smooth muscle. In one species alone, Eggermont et al. (9) compared PLB and SERCA mRNA as well as protein expression across different smooth muscle types and found that in contrast to stable SERCA2 levels, PLB mRNA levels varied 12-fold between different tissues, with low and very low levels in pulmonary artery and aorta, respectively.
Our findings do raise the question of how SERCA regulation occurs in human ASM. In coronary artery smooth muscle, there is evidence of CaMKII phosphorylation of SERCA with accompanying increase in SERCA activity, even though PLB could not be detected in that tissue (12) . Indeed, even in cardiac muscle (where PLB is well known to play an important role), CaMKII-mediated SERCA phosphorylation (at a Ser38 site) has been demonstrated (23, 36, 39) . Previous studies in SR vesicles from bovine trachea show SERCA modulation by a Ca 2ϩ /CaM protein kinase (7) . In our recent study, we found that even with decreased PLB expression via siRNA, the rate of Ca 2ϩ reuptake is modulated by inhibitors of CaM and CaMKII (30) . These diverse data suggest that direct phosphorylation of SERCA protein may occur in the absence of PLB. The results of the present study in human ASM showing decreased SR reuptake (both in ASM cells as well as for 45 Ca uptake in cell homogenates) in the presence of the CaMKII inhibitor KN-93 do indicate such a mechanism of SERCA regulation. In addition to direct effect of regulatory mechanisms on SERCA protein itself, indirect effects on Ca 2ϩ reuptake may occur via other mechanisms such as mitochondrial Ca 2ϩ buffering. These alternative scenarios remain to be examined.
Inflammation and [Ca 2ϩ ] i regulation. Although diseases such as asthma are likely multifactorial in origin, there is clearly a role for inflammation and its effects on ASM structure and function. In this regard, one cytokine abundantly produced in inflamed airway and well-studied in airway inflammation is antagonist (KN-93) , and Ca 2ϩ uptake was evaluated over a 45-min period. SERCA inhibition by thapsigargin was used as a control for inhibited reuptake. All values for CaM, KN-93, and thapsigargin are significantly different from control (n ϭ 4). Fig. 6 . Effect of the proinflammatory cytokines TNF␣ and IL-13 on PLB and SERCA2 expression in human ASM. In spite of overnight exposure to either cytokine, PLB remained undetectable in ASM, whereas SERCA2 expression was decreased. Bar graphs summarize data from 4 samples. Values are means Ϯ SE. *Significant cytokine effect (P Ͻ 0.05).
TNF␣ (10, 19) . TNF␣ has been shown to increase both agonist-induced [Ca 2ϩ ] i and force in ASM of several species (1, 5, 20, 29, 38) . These effects involve augmentation of second messenger-mediated SR Ca 2ϩ release (3, 4, 13, 34 ] i , it is somewhat surprising that there is currently no information on the effect of either TNF␣ or IL-13 on SERCA in ASM of any species. In the heart, TNF␣-induced diastolic dysfunction is thought to be mediated at least in part by inhibition of SERCA activity. Furthermore, in cardiac muscle, TNF␣ has been shown to decrease SERCA expression. The results of the present study showing decreased SERCA expression in human ASM with exposure to TNF␣ and IL-13 are novel in this regard and suggest an additional mechanism by which cytokines increase [Ca 2ϩ ] i in ASM. Both TNF␣ and IL-13 are known to activate a number of intracellular signaling cascades. In other cell types, TNF␣ can activate CaMKII. Assuming such activation occurs in human ASM, we would have expected accelerated SR Ca 2ϩ reuptake, Fig. 8 . Effect of CaMKII inhibition on TNF␣ and IL-13 induced changes in SR Ca 2ϩ reuptake. In TNF␣-or IL-13-exposed ASM cells where the rate of fall of [Ca 2ϩ ]i responses to ACh or bradykinin was slowed, repetition of the protocol in the presence of KN-93 did not significantly alter the rate of fall, suggesting that CaMKII is not the major mechanism by which either cytokine affects SR Ca 2ϩ reuptake in human ASM. Values are means Ϯ SE. *Significant cytokine effect, #significant KN-93 effect (P Ͻ 0.05). while we observed the opposite. It is possible that other mechanisms activated by TNF␣ may dominate and produce slowing of SERCA, considering the lack of additional effect of the CaMKII inhibitor KN-93 on TNF␣-or IL-13-induced slowing of reuptake. Alternatively, decreased SERCA expression alone may sufficiently explain slowed reuptake. These alternative scenarios remain to be explored.
Regardless of the mechanisms involved, the results of the present study suggest an additional target for cytokines by which they increase [Ca 2ϩ ] i in ASM. For example, if TNF␣ increases SR Ca 2ϩ release, but simultaneously decreases SR Ca 2ϩ reuptake, then total [Ca 2ϩ ] i could be expected to rise. Furthermore, the eventual depletion of SR Ca 2ϩ stores would only enhance store-operated Ca 2ϩ entry, which is already known to be enhanced by cytokines such as TNF␣ (regardless of cytokine effects on SR).
